Upcoming Events

July 31, 2019 • 8:00am ET

2019 Annual Meeting of Stockholders

Boston, MA

Past Events

June 6, 2019 • 3:30 pm ET

Jefferies 2019 Healthcare Conference

New York, NY

Webcast

May 21, 2019 • 11:30 am ET

2019 RBC Capital Markets Global Healthcare Conference

New York, New York

Webcast

May 10, 2019 • 8:00 am ET

First Quarter 2019 Financial Results Conference Call

April 8, 2019 • 1:30 pm GMT

2019 H.C. Wainwright Global Life Sciences Conference

London, U.K.

Webcast

March 13, 2019 • 10:40 am ET

Cowen and Company 39th Annual Health Care Conference

Boston

Webcast

March 12, 2019 • 8:00 am ET

Full-Year 2018 Investor Call and Corporate Update

More past events »

Pieris Drug Pipeline

Pieris pipeline includes multiple fully proprietary as well as partnered programs in a number of different therapeutic areas. Our most advanced Anticalin program PRS-080 (hepcidin antagonist to treat anemia), our advanced respiratory program PRS-060 (1st-in-class inhaled IL4Ra antagonist to treat asthma) and several of our immuno-oncology (IO) multispecific programs (PRS-300 series), led by PRS-343 (a HER2/4-1BB bispecific), are examples of our fully proprietary programs. As we continue to build our IO and Respiratory franchises, we aim to ultimately develop Pieris into a fully-integrated pharmaceutical company by retaining commercial rights to several of these programs in major markets. For this purpose, we are also joining forces with other pharmaceutical companies, as exemplified by our strategic co-development IO alliance with Servier, with PRS-332 (PD1-based dual checkpoint inhibitor) as the lead program of this collaboration, to which we retain full US rights.

For more information about our pipeline, click here.

Upcoming Events

Past Events

Q1 2019Quarterly Results

Q4 2018Quarterly Results

Q1 2019
Quarterly Results

Q4 2018
Quarterly Results